| 15.22 0.24 (1.6%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 25.73  |
1-year : | 31.33 |
| Resists | First : | 22.03 |
Second : | 26.82 |
| Pivot price | 19.65 |
|||
| Supports | First : | 14.27 |
Second : | 11.88 |
| MAs | MA(5) : | 16.49 |
MA(20) : | 20.72 |
| MA(100) : | 17.9 |
MA(250) : | 13.2 |
|
| MACD | MACD : | -1.8 |
Signal : | -1 |
| %K %D | K(14,3) : | 7.1 |
D(3) : | 9.5 |
| RSI | RSI(14): 26.4 |
|||
| 52-week | High : | 28 | Low : | 6.56 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ JBIO ] has closed above bottom band by 9.5%. Bollinger Bands are 123.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 15.4 - 15.48 | 15.48 - 15.56 |
| Low: | 14.06 - 14.17 | 14.17 - 14.27 |
| Close: | 15.06 - 15.22 | 15.22 - 15.37 |
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.
Tue, 09 Jun 2026
[SCHEDULE 13D/A] Jade Biosciences, Inc. Amended Major Shareholder Report - Stock Titan
Sat, 06 Jun 2026
Jade Biosciences Completes Public Offering of 11.5 Million Shares, Raising $172.5 Million for Autoimmune Disease Therapies - Moomoo
Fri, 05 Jun 2026
Jade Biosciences plans public offering, pre-funded warrants - MSN
Fri, 05 Jun 2026
Jade Biosciences Completes Public Offering of 11.5 Million Shares, Raising $172.5 Million for Autoimmune Disease Therapies - Quiver Quantitative
Fri, 05 Jun 2026
Biotech Jade Biosciences raises $172.5M for autoimmune trials - Stock Titan
Fri, 05 Jun 2026
Number of shareholders of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 101.3 (%) |
| Shares Short | 3,400 (K) |
| Shares Short P.Month | 3,060 (K) |
| EPS | -2.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.01 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -100 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -5.79 |
| PEG Ratio | 0 |
| Price to Book value | 2.53 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.52 |
| Dividend | 2.4 |
| Forward Dividend | 0 |
| Dividend Yield | 15.7% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|